Equities analysts expect Viewray Inc (NASDAQ:VRAY) to report earnings of ($0.26) per share for the current quarter, Zacks Investment Research reports. Six analysts have provided estimates for Viewray’s earnings, with estimates ranging from ($0.32) to ($0.18). Viewray posted earnings of ($0.17) per share during the same quarter last year, which would indicate a negative year over year growth rate of 52.9%. The business is scheduled to report its next earnings report on Thursday, March 12th.

According to Zacks, analysts expect that Viewray will report full year earnings of ($1.13) per share for the current year, with EPS estimates ranging from ($1.20) to ($1.05). For the next year, analysts anticipate that the firm will post earnings of ($0.96) per share, with EPS estimates ranging from ($1.16) to ($0.65). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Viewray.

Viewray (NASDAQ:VRAY) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.06. The firm had revenue of $20.90 million for the quarter, compared to analyst estimates of $20.66 million. Viewray had a negative net margin of 110.61% and a negative return on equity of 75.41%. The business’s revenue for the quarter was up 18.1% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.39) EPS.

VRAY has been the topic of a number of research reports. ValuEngine cut Viewray from a “buy” rating to a “hold” rating in a research note on Friday, November 1st. Jefferies Financial Group dropped their price objective on Viewray from $14.00 to $7.00 and set a “buy” rating for the company in a research note on Friday, August 9th. Mizuho reiterated a “buy” rating and issued a $9.00 price objective on shares of Viewray in a report on Tuesday. Piper Jaffray Companies set a $6.00 target price on Viewray and gave the stock a “buy” rating in a research note on Tuesday, October 15th. Finally, Zacks Investment Research lowered Viewray from a “strong-buy” rating to a “hold” rating in a research note on Saturday, November 16th. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $7.30.

Hedge funds have recently modified their holdings of the business. Park West Asset Management LLC grew its stake in shares of Viewray by 87.3% in the second quarter. Park West Asset Management LLC now owns 7,615,325 shares of the company’s stock worth $67,091,000 after acquiring an additional 3,549,255 shares in the last quarter. Millennium Management LLC boosted its holdings in Viewray by 114.7% in the third quarter. Millennium Management LLC now owns 1,549,067 shares of the company’s stock valued at $4,492,000 after purchasing an additional 827,592 shares during the period. Perceptive Advisors LLC boosted its holdings in Viewray by 13.5% in the second quarter. Perceptive Advisors LLC now owns 5,455,243 shares of the company’s stock valued at $48,061,000 after purchasing an additional 649,593 shares during the period. D. E. Shaw & Co. Inc. boosted its holdings in Viewray by 204.3% in the second quarter. D. E. Shaw & Co. Inc. now owns 713,178 shares of the company’s stock valued at $6,283,000 after purchasing an additional 478,819 shares during the period. Finally, Granite Investment Partners LLC grew its stake in Viewray by 35.0% during the 2nd quarter. Granite Investment Partners LLC now owns 1,428,821 shares of the company’s stock worth $12,588,000 after purchasing an additional 370,667 shares in the last quarter.

Viewray stock opened at $3.40 on Friday. The company has a market capitalization of $329.54 million, a PE ratio of -3.47 and a beta of 1.09. The company has a debt-to-equity ratio of 0.62, a quick ratio of 2.58 and a current ratio of 3.70. Viewray has a fifty-two week low of $2.12 and a fifty-two week high of $9.76. The firm has a 50 day moving average price of $2.79 and a 200 day moving average price of $5.57.

Viewray Company Profile

ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.

Recommended Story: What is the operating income formula?

Get a free copy of the Zacks research report on Viewray (VRAY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Viewray (NASDAQ:VRAY)

Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.